Rheumatoid arthritis has long confounded medicine with its stubborn complexity — the immune system turned against the very body it was meant to protect. Now, a plant-derived compound called obakulactone has demonstrated in rat models that joint inflammation and damage can be meaningfully reduced by correcting disrupted fatty acid metabolism and quieting overactive immune cells. The discovery points toward a molecular target, the protein ACOT1, that prior therapeutic strategies have largely ignored, opening a new corridor of possibility for the roughly one percent of humanity living with this c